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Increased hypoglycemia associated with renal failure during continuous
intravenous insulin infusion and specialized nutritional support
Abstract
Objective: To evaluate glycemic control for critically ill, hyperglycemic trauma patients with renal failure who
received concurrent intensive insulin therapy and continuous enteral (EN) or parenteral nutrition (PN).
Methods: Adult trauma patients with renal failure, who were given EN or PN concurrently with continuous
graduated intravenous regular human insulin (RHI) infusion for at least 3 days were evaluated. Our
conventional RHI algorithm was modified for those with renal failure by allowing greater changes in blood
glucose concentrations (BG) before the infusion rate was escalated. BG was determined every 1-2 hours while
receiving the insulin infusion. BG control was evaluated on the day prior to RHI infusion and for a maximum
of 7 days while receiving RHI. Target BG during the RHI infusion was 70 to 149 mg/dL (3.9 to 8.3 mmol/L).
Glycemic control and incidence of hypoglycemia for those with renal failure were compared to a historical
cohort of critically ill, hyperglycemic trauma patients without renal failure given our conventional RHI
algorithm.
Results: Twenty-one patients with renal failure who received the modified RHI algorithm were evaluated and
compared to forty patients without renal failure given our conventional RHI algorithm. Average BG was
significantly greater for those with renal failure (133 + 14 mg/dL or 7.3 + 0.7 mmol/L) compared to those
without renal failure (122 + 15 mg/dL or 6.8 + 0.8 mmol/L), respectively (p < 0.01). Patients with renal
failure experienced worsened glycemic variability with 16.1 + 3.3 hours/day within the target BG range, 6.9 +
3.2 hours/day above the target BG range, and 1.4 + 1.1 hours below the target BG range compared to 19.6 +
4.7 hours/day (p < 0.001), 3.4 + 3.0 hours/day (p < 0.001), and 0.7 + 0.8 hours/day (p < 0.01) for those
without renal failure, respectively. Moderate hypoglycemia (< 60 mg/dL or < 3.3 mmol/L) occurred in 76%
of patients with renal failure compared to 35% without renal failure (p < 0.005). Severe hypoglycemia (BG <
40 mg/dL or < 2.2 mmol/L) occurred in 29% of patients with renal failure compared to none of those
without renal failure (p < 0.001).
Conclusion: Despite receiving a modified RHI infusion, critically ill trauma patients with renal failure are at
higher risk for developing hypoglycemia and experience more glycemic variability than patients without renal
failure.
Disciplines
Pharmacy and Pharmaceutical Sciences
Authors
Roland N. Dickerson, Leslie A. Hamilton, Kathryn A. Connor, George O. Maish, Martin A. Croce, Gayle
Minard, and Rex O. Brown
This article is available at Fisher Digital Publications: http://fisherpub.sjfc.edu/pharmacy_facpub/31
 1 
Increased Hypoglycemia Associated with Renal Failure during Continuous Intravenous 
Insulin Infusion and Specialized Nutrition Support 
Roland N. Dickerson, PharmD* 
Leslie A. Hamilton, PharmD* 
Kathryn A. Connor, PharmD* 
George O. Maish, III MD  
Martin A. Croce, MD  
Gayle Minard, MD  
Rex O. Brown, PharmD* 
From the Departments of Clinical Pharmacy* and Surgery , University of Tennessee 
Health Science Center, Memphis, Tennessee  
 
Presented, in part, at the Ninth Annual Nutrition Week of the American Society for 
Parenteral and Enteral Nutrition, February 9, 2010, Las Vegas, NV 
 
Corresponding Author: 
Roland N. Dickerson, Pharm.D., BCNSP, FACN, FCCP 
University of Tennessee Health Science Center 
910 Madison Ave, Room 308 






Objective: To evaluate glycemic control for critically ill, hyperglycemic trauma patients 
with renal failure who received concurrent intensive insulin therapy and continuous 
enteral (EN) or parenteral nutrition (PN).  
Methods: Adult trauma patients with renal failure, who were given EN or PN 
concurrently with continuous graduated intravenous regular human insulin (RHI) 
infusion for at least 3 days were evaluated. Our conventional RHI algorithm was 
modified for those with renal failure by allowing greater changes in blood glucose 
concentrations (BG) before the infusion rate was escalated.  BG was determined every 1-
2 hours while receiving the insulin infusion. BG control was evaluated on the day prior to 
RHI infusion and for a maximum of 7 days while receiving RHI. Target BG during the 
RHI infusion was 70 to 149 mg/dL (3.9 to 8.3 mmol/L).  Glycemic control and incidence 
of hypoglycemia for those with renal failure were compared to a historical cohort of 
critically ill, hyperglycemic trauma patients without renal failure given our conventional 
RHI algorithm. 
Results: Twenty-one patients with renal failure who received the modified RHI 
algorithm were evaluated and compared to forty patients without renal failure given our 
conventional RHI algorithm. Average BG was significantly greater for those with renal 
failure (133 + 14 mg/dL or 7.3 + 0.7 mmol/L) compared to those without renal failure 
(122 + 15 mg/dL or 6.8 + 0.8 mmol/L), respectively (p < 0.01). Patients with renal failure 
experienced worsened glycemic variability with 16.1 + 3.3 hours/day within the target 
BG range, 6.9 + 3.2 hours/day above the target BG range, and 1.4 + 1.1 hours below the 
target BG range compared to 19.6 + 4.7 hours/day (p < 0.001), 3.4 + 3.0 hours/day (p < 
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0.001), and 0.7 + 0.8 hours/day (p < 0.01) for those without renal failure, respectively. 
Moderate hypoglycemia (< 60 mg/dL or < 3.3 mmol/L) occurred in 76% of patients with 
renal failure compared to 35% without renal failure (p < 0.005). Severe hypoglycemia 
(BG < 40 mg/dL or < 2.2 mmol/L) occurred in 29% of patients with renal failure 
compared to none of those without renal failure (p < 0.001).  
Conclusion: Despite receiving a modified RHI infusion, critically ill trauma patients with 
renal failure are at higher risk for developing hypoglycemia and experience more 
glycemic variability than patients without renal failure.  
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Introduction  
 Critically ill trauma patients often develop insulin resistance and experience 
hyperglycemia.[1] Despite controversy regarding the optimal target blood glucose 
concentration  range for various critically ill patient populations[2,3], evidence of 
improved morbidity and mortality has been established for critically ill trauma patients 
who receive modest glycemic control (e.g., < 150 mg/dL or 8.3 mmol/L).[2,4-6]  
Hyperglycemia during critical illness may be further complicated by renal failure (acute 
kidney injury or the presence of chronic kidney disease). Patients with renal failure have 
been shown to develop hyperglycemia and insulin resistance.[7-9] Conversely, patients 
with renal failure have been reported to be susceptible to the development of 
hypoglycemia[10-13] with decreased insulin requirements compared to those with 
normal renal function.[14,15]  As a result of these divergent mechanisms, the intent of 
this retrospective study was to evaluate the extent of glycemic control and incidence of 
hypoglycemia for critically ill, hyperglycemic trauma patients with renal failure who 
received concurrent intensive insulin therapy and specialized nutrition support.  
 
Materials and Methods 
 Adult patients, > 18 years of age, admitted to the Presley Memorial Trauma 
Center at the Regional Medical Center at Memphis between February, 2008 until May 
2009, who were referred to the Nutrition Support Service for specialized nutrition support, 
and who required intensive insulin therapy were identified for potential inclusion into the 
study. Patients studied included those with acute kidney injury (AKI) according to the 
RIFLE criteria[16] or with Stage V chronic kidney disease (CKD) as evidenced by a 
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history of outpatient hemodialysis, treated for hyperglycemia with a graduated 
continuous intravenous insulin infusion algorithm, and concurrently given continuous 
enteral nutrition (EN) or parenteral nutrition (PN). Patients were excluded if they 
received supplemental intermediate-acting or long-acting insulin therapy (e.g., neutral 
protamine hagedorn or insulin glargine) during the study observation period, received 
intermittent or bolus EN, had an ad-libitum oral diet intake > 500 kcal/d (2,093 kJ/d), or 
received < 72 hours of continuous intravenous insulin therapy. Adult patients without 
renal failure admitted to the trauma intensive care unit who received our conventional 
graduated intravenous infusion algorithm (Table 1) from February, 2006 to April, 2007 
served as a historical cohort control group.[17]  Determination for the need for 
hemodialysis was done by the nephrology consultative service. Conventional 
hemodialysis was completed within a four hour time period with the patients re-evaluated 
daily for additional hemodialysis or hemofiltration. Continuous renal replacement therapy 
or peritoneal dialysis was not available at our institution. 
 Patients who were initially selected to receive continuous intravenous insulin 
infusion therapy included those who had a serum or blood glucose concentration (BG) > 
180 mg/dL (10 mmol/L) before the initiation of specialized nutrition support, 
hyperglycemia > 150 mg/dL (8.3 mmol/L) with a past medical history of diabetes 
mellitus, or persistent hyperglycemia > 150 mg/dL (8.3 mmol/L) during EN or PN 
despite attempts to minimize the hyperglycemia. Efforts to reduce hyperglycemia 
included the use of a diabetic EN formulation whenever a specialized EN formula (e.g., 
immune-enhancing diet or renal failure formula) was not indicated or a low dextrose-
containing PN solution with added regular human insulin, elimination of dextrose from 
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large volume parenteral solutions and small volume parenteral medications whenever 
possible, and implementation of either an insulin infusion or sliding scale regular human 
insulin as previously described.[17]  Point-of-care BG concentrations were determined 
hourly by the glucose dehydrogenase method using the Accu-Chek® Inform System 
(Roche Diagnostics Corporation, Indianapolis, IN, USA) during the infusion.  
 The continuous intravenous insulin infusion was prepared by mixing 100 mL of 
0.9% sodium chloride injection with 100 units of regular human insulin to achieve a final 
concentration of 1 unit per mL. The insulin infusion was initiated at a rate of 2 to 4 
units/h and titrated thereafter in an effort to maintain the BG within the target range of 70 
to 149 mg/dL (3.9 to 8.3 mmol/L). Time to achieve BG control was determined from the 
difference between the hours of initiation of the insulin infusion to the hour whereby two 
consecutive hourly BG measurements were less than 150 mg/dL (8.3 mmol/L). After 
stability in BG concentrations within the target BG range with a consistent RHI infusion 
rate and the goal nutrition support regimen was reached, BG measurement monitoring 
was extended from hourly to every two hours.  Moderate hypoglycemia and severe 
hypoglycemia were defined as a BG concentration of < 60 mg/dL (3.3 mmol/L) and < 40 
mg/dL (2.2 mmol/L), respectively.   
 The safety and efficacy of our graduated intravenous insulin infusion protocol for 
our critically ill trauma patients without renal failure receiving specialized nutrition 
support has been previously established[17] and served as the historical comparative 
control group for this study.  We empirically observed frequent development of severe 
hypoglycemia when our original insulin infusion algorithm was employed for trauma 
patients with renal failure. Resultantly, the algorithm was modified for trauma patients 
 7 
with renal failure by allowing a greater changes in BG (e.g., 50 mg/dL or 2.8 mmol/L 
instead of 25 mg/dL or 1.4 mmol/L increments) before the insulin infusion rate was 
escalated. Details regarding the modified and conventional graduated intravenous insulin 
infusion algorithms are given in Table 1.  
 Patients were preferentially given EN by a small-bore, nasogastric/nasoenteric 
feeding tube or jejunostomy. PN was given when the patient was unable to tolerate EN or 
when EN was contraindicated. If the EN or PN regimen was temporarily or abruptly 
discontinued, a 5% dextrose-containing large-volume parenteral solution was 
administered at the same infusion rate as the feeding formulation in an effort to prevent 
hypoglycemia. If the patient’s PN or EN was to be discontinued for any significant 
portion of time, the continuous intravenous insulin infusion was discontinued.  Serum 
laboratories were obtained from each patient on a daily basis. The blood was obtained at 
approximately 0300 via an indwelling arterial or venous catheter while the patient lay 
supine in bed. Laboratory tests were ordered by the patient's primary service or the 
Nutrition Support Service and performed by the hospital laboratory as part of the 
patient’s routine clinical care.  The Injury Severity Score[18] was obtained from the 
Trauma Registry at the Regional Medical Center at Memphis. The presence of sepsis was 
documented according to the 2001 International Sepsis Definitions Conference.[19] 
 At the time of enrollment into the study, the patient’s hospital chart, electronic 
medical records, and bedside clinical data were reviewed. Data were recorded for the day 
prior to starting the intravenous insulin infusion and for a maximum of eight days while 
receiving the infusion. Mean BG measurements were averaged for each day. Data 
recorded for Day 0 was considered a partial day beginning when the intravenous insulin 
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infusion was initiated. The number of units of regular human insulin given daily was also 
recorded. If the patient received PN, the amount of insulin received from the PN 
formulation was added to amount received from the infusion to determine total units of 
regular human insulin received.  
 The study was approved and conducted in accordance with the guidelines 
established by the Institutional Review Board of the University of Tennessee Health 
Science Center.  Because all measurements from this observational study were performed 
as part of the routine clinical care of the patient and because confidentiality procedures 
for the patient were maintained, the requirement for informed consent was waived. Data 
were analyzed using SigmaPlot® for Windows version 11.2 (Systat Software, Inc., Point 
Richmond, CA). Data were evaluated for normality of distribution by using the Shapiro-
Wilk test. Independent variables were compared by applying the t-test for unpaired 
variables if the data were normally distributed or Mann-Whitney U test if they were not 
normally distributed. Two-way repeated measures analysis of variance with post-hoc 
pair-wise comparisons using the Student-Newman-Keuls test were used for comparing 
serial data within and between groups.  Differences between groups for nominal data 
were analyzed by either Chi-Square analysis or Fisher Exact test. Continuous data are 
expressed as mean + S.D.  A p value of 0.05 or less indicated statistical significance. 
 
Results 
 Twenty-one consecutive hyperglycemic adult patients admitted to the trauma 
intensive care unit from February 2008 to May 2009, referred to the nutrition support 
service, who developed AKI (n=18) or had pre-existing Stage V CKD (n=3) and who 
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required the modified intravenous insulin infusion algorithm were evaluated. Sepsis or 
ischemia from hemorrhagic or hypovolemic shock were responsible for the pathogenesis 
of acute kidney injury in these patients.  Eight patients required intermittent hemodialysis 
during the continuous intravenous insulin therapy. Data from a previously published 
study[17] with forty consecutive hyperglycemic adult patients without renal failure 
admitted to the trauma intensive care unit who received our conventional intravenous 
infusion algorithm served as a historical control group (Table 2). All patients in both 
groups were ventilator-dependent and none had evidence of significant liver disease. 
Patients were given fentanyl and midazolam for analgesia and sedation.  Eight patients 
with renal failure and twenty-two patients in the historical control group initially received 
propofol for the management of increased intracranial pressure from traumatic brain 
injury. A significant proportion of each population had a past medical history of diabetes 
mellitus (52% versus 40% for the renal failure and normal renal function groups, 
respectively) and was older than our typical trauma patient population[20,21] with a 
mean age of 60 and 57 years, respectively (Table 2). No differences in age, weight, injury 
severity score, presence of diabetes mellitus, incidence of sepsis, or other clinical markers 
that may explain differences in glycemic control were found between groups (Table 2).  
The renal failure group had a higher proportion of African-Americans (57%) compared to 
25% of patients in the control group (p = 0.04). Not surprisingly, mean serum creatinine 
concentration was significantly greater for the renal failure group (e.g., 3.2 mg/dL versus 
1.2 mg/dL or 283 μmol/L versus 106 μmol/L, respectively, p < 0.001) and the predicted 
creatinine clearance by Cockroft-Gault equation[22] was also substantially lower (36 
mL/min versus 73 mL/min, respectively, p < 0.001; Table 2). 
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 The continuous intravenous insulin infusion was started approximately 3 days 
after initiation of specialized nutrition support for both groups after failure to control 
hyperglycemia with conventional conservative management. Patients from both groups 
required several days of a continuous intravenous insulin infusion for an average of ~100 
units daily and received similar amounts of carbohydrate (Table 3; Figure 1).  Patients 
achieved the target BG concentrations within several hours for both groups (p = N.S.).  
Mean BG concentration during the observation period for the renal failure group was 
greater than the control population (133 mg/dL versus 122 mg/dL or 7.3 mmol/L versus 
6.8 mmol/L, p < 0.01, Table 3).  Average daily BG concentrations were also greater for 
the AKI group compared to control (Figure 1, p < 0.05). 
 Differences in BG control and variability were evident as patients with renal 
failure had less time within the target BG concentration range (16 hrs/d versus 20 hrs/d, 
respectively, Table 3; p < 0.001).  Additionally, patients with renal failure exhibited twice 
as much time above (7 hrs versus 3 hrs, respectively, p < 0.001) and below (1.4 versus 
0.7 hrs, respectively, p < 0.01) the target BG concentration range (Table 3).    
Hypoglycemic (BG < 60 mg/dL or 3.3 mmol/L) episodes were evident in 56 of 
2,536 (2.21%) BG measurements for patients with renal failure compared to 23 of 4,140 
(0.56%) for those without renal failure (p < 0.001). Seven of the 56 episodes of 
hypoglycemia for patients with renal failure were attributed to protocol violations. Severe 
hypoglycemia (BG < 40 mg/dL or 2.2 mmol/L) occurred in 9 of 2,536 (0.35%) for those 
with renal failure in contrast to 0 of 4,140 BG measurements for those without renal 
failure (p < 0.001).  Two hypoglycemic patients with renal failure were reported to be 
symptomatic with improvement following administration of 50 g of intravenous dextrose. 
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Twenty-nine percent of patients with renal failure developed at least one episode of 
severe hypoglycemia whereas none of those without renal failure developed severe 
hypoglycemia (p < 0.001, Table 3).  There were no significant differences in patient 
characteristics, average BG concentration, injury severity score, amount of insulin or 
carbohydrate received among those who developed severe hypoglycemia compared to 
those who did not experience severe hypoglycemia (p = NS, Table 4).  None of the 
patients received medications commonly known to potentially induce hypoglycemia (e.g., 
trimethoprim-sulfamethoxazole, pentamidine, oral sulfonylureas, metformin, 
levofloxacin, quinine, or disopyramide)[23] during the study period. Five patients from 
each group received intravenous vasopressor and/or inotropic support. None of the 
patients received other medications known to induce hyperglycemia (e.g., corticosteroids, 
thiazide diuretics, protease inhibitors, β-adrenergic blockers, clozapine, or olanzapine)[24] 
during the study observation period. 
 
Discussion 
Hyperglycemia is a common complication in critically ill trauma patients 
receiving specialized nutrition support.[17] If the hyperglycemia remains uncontrolled, 
adverse effects from hyperglycemia may occur independently of the extent of injury.[25-
28]  Therefore, critically ill, hyperglycemic trauma patients receiving EN or PN are also 
given a continuous intravenous insulin infusion in an effort to lower their BG to less than 
140 to 150 mg/dL (7.8 to 8.3 mmol/L).[4-6] However, recent trends towards an 
increasing prevalence of hypoglycemia with intensive insulin therapy[2,29-32] has 
prompted clinicians to critically re-evaluate their current management of hyperglycemia. 
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Although the development of severe hypoglycemia has been associated with increased 
mortality[11,13,33-36], this association is not conclusively causal and may be attributable 
to impending death from multiple organ failure syndrome rather than an incidental short-
term episode of hypoglycemia from intensive insulin therapy.[37-39] Even with the lack 
of conclusive evidence of increased mortality from hypoglycemia, severe hypoglycemia 
can result in neuroglycopenic consequences including seizures, coma, and death and 
should be avoided. 
Defining hypoglycemia solely on the serum or blood glucose concentration can be 
misleading as the glycemic threshold for physiological responses to hypoglycemia such 
as glycemic counter-regulatory hormone production, initiation of autonomic and 
neurologic symptoms, and onset of deterioration in cognitive function is variable among 
normal humans.[40]  A BG of ~70 mg/dL (3.9 mmol/L) or less has been shown to 
increase glycemic counter-regulatory hormone secretion without the presence of 
autonomic or neuroglycopenic symptoms until a BG of ~ 60 mg/dL (3.3 mmol/L) or less 
was achieved.[40]  Based on these data, we defined a BG of less than 60 mg/dL (3.3 
mmol/L) as clinically relevant (e.g., moderate hypoglycemia) whereby the intravenous 
insulin infusion was to be stopped and additional intravenous glucose immediately given 
to the patient irrespective of presence or absence of hypoglycemic symptoms (Table 1).  
The definition of severe hypoglycemia (BG < 40 mg/dL or 2.2 mmol/L) concurs with the 
criteria used in the large intensive insulin therapy trials[2,3,29-31] and is clearly 
associated with cognitive function decline[40] and potentially seizures, coma, and death. 
After observing several cases of severe hypoglycemia with the use of our 
conventional graduated continuous insulin infusion[17] in patients with renal failure, we 
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modified our original algorithm by allowing greater changes in BG before the insulin 
infusion dose was escalated in an effort to reduce the risk for hypoglycemia (Table 1).  
With use of this modified algorithm, average daily BG concentrations were significantly 
higher for those with renal failure (Figure 1).  Despite a higher mean BG concentration, 
three-fourths of our hyperglycemic trauma patients with renal failure experienced at least 
one episode of moderate hypoglycemia and nearly one-third had an episode of severe 
hypoglycemia (Table 3). This high prevalence of hypoglycemia was unlike that observed 
in our control cohort population whereby only one third of the population experienced an 
episode of moderate hypoglycemia and none developed severe hypoglycemia (Table 3). 
Data extracted from the large intensive insulin therapy trials[2,3,29-31] may indirectly 
support our observations. Table 5 summarizes the reported incidence of renal failure in 
these trials along with the incidence of severe hypoglycemia. Both the Leuven 2[41] and 
VISEP[29] trials reported the highest incidence of acute kidney injury at 20% and 31% 
respectively of those who received intensive insulin therapy. These two investigations 
also had the highest incidence of severe hypoglycemia (18.7% and 17%, respectively) of 
the major trials. However, further investigation by these groups is necessary to be certain 
whether this association between renal failure and severe hypoglycemia is congruent with 
our findings as multiple factors may have been involved in the development of 
hypoglycemia.  
Less hypoglycemia occurred for our patients without significant renal failure 
despite a more aggressive continuous intravenous insulin infusion algorithm (Table 1). 
However, it is additionally plausible that the observed rate of hypoglycemia may be 
attributable to the insulin infusion algorithm itself used for patients with renal failure. 
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Although the escalation in insulin infusion rate is slower for the modified algorithm, the 
de-escalation dosing portion of the algorithm remained the same. Following the analysis 
of these data as part of our quality improvement procedures for the Nutrition Support 
Service at the Regional Medical Center at Memphis, the continuous intravenous insulin 
infusion algorithm designed for patients with renal failure as described in Table 1 was 
terminated with the subsequent re-design and implementation of a new algorithm in an 
effort to avoid hypoglycemia while striving to achieve acceptable glycemic control is 
ongoing. Whether altering the algorithm to reflect a de-escalation in insulin infusion rate 
sooner for patients without renal failure will result in less hypoglycemia with 
maintenance of BG < 150 mg/dL (8.3 mmol/L) requires further study. 
The presence of AKI or CKD complicates glycemic control.  Worsening 
hyperglycemia from insulin resistance with an increase in associated mortality has been 
reported for patients with AKI.[7-9] Conversely, insulin is metabolized, in part, by the 
kidney and reduced renal function has resulted in a prolonged elimination half-life[14,42-
44] which may result in hypoglycemia.[32] These divergent metabolic effects magnify 
the difficulty for achieving safe and effective glycemic control for critically ill trauma 
patients with AKI or CKD receiving specialized nutrition support.  Patients with renal 
failure in our study had less favorable glycemic control than control patients with 
significantly less hours in the target BG range (16 hrs versus 20 hours daily) and twice as 
many average hours above (7 hrs versus 3 hrs) and below (1.4 hrs versus 0.7 hrs) the 
target range (Table 3).   
 The kidney has an important role in the metabolism of insulin and accounts for 
approximately 50% of its clearance from the systemic circulation.[45]  Insulin is readily 
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filtered by the glomerulus and then reabsorbed or degraded by the proximal peritubular 
epithelial and endothelial cell membranes with less than 1% of the filtered insulin 
appearing in the urine.[46] About one-third of the total renal clearance of insulin occurs 
from receptor-mediated post-glomerular, peritubular circulation[45] resulting in greater 
renal clearance of insulin than the glomerular filtration rate.[46]  When the glomerular 
filtration rate decreases to ~40 to 50 mL/min, renal insulin clearance substantially 
declines.[43,46]  
Impaired insulin clearance from renal failure may not be the sole factor leading to 
or influencing recovery from hypoglycemia during continuous intravenous insulin 
infusion.  Historical studies suggested renal glucose release accounted for only 10% of 
total glucose appearance and supported the concept that the kidney was a minor 
gluconeogenic organ.[47,48]  However, more recent data indicates that the kidney 
represents an important organ in glucose regulation.[49-52] Isotope studies in healthy 
subjects demonstrated that renal glucose release accounts for 28% of systemic glucose 
appearance in the basal post-absorptive state.[52]  During hypoglycemia, increases in 
plasma glucagon and circulating levels of catecholamines occur in an effort to increase 
blood glucose concentration via glycogenolysis and gluconeogenesis.  Autonomic 
nervous system activation from hypoglycemia will result in gluconeogenesis and net 
glucose release from the kidney.[49-52]  
 These phenomena may explain previous observations that include a five-fold 
higher incidence in hypoglycemia for insulin-dependent diabetics with a serum 
creatinine > 1.5 mg/dL (133 µmol/L) compared to insulin-dependent diabetics without 
kidney injury[53], decreased insulin requirements of diabetic patients with impaired renal 
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function[14], hypoglycemic events observed in non-diabetic patients with renal 
insufficiency[46,54], a four-fold increase in the risk of hypoglycemia during intensive 
insulin therapy for patients with AKI[55], an odds ratio of 14 for hypoglycemia for 
patients receiving intensive insulin therapy during continuous renal replacement 
therapy[32], and data before the era of intensive insulin therapy indicating that half of 
hospitalized patients with hypoglycemia also had CKD.[11]  These metabolic aberrations 
may also explain the 76% incidence of moderate hypoglycemia and 29% incidence of 
severe hypoglycemia for those with renal failure despite receiving a “modified” 
intravenous insulin infusion algorithm in our study.  
 This study has its limitations. The use of a historical control population that 
received a continuous intravenous insulin infusion exhibited differences from the renal 
failure group beyond renal function including a higher proportion of Caucasians as 
opposed to the current study with a higher proportion of African-Americans and a higher 
mortality rate than the current renal failure group.  The higher than expected mortality 
rate of the historical control group was likely due to our extremely stringent use of 
continuous intravenous insulin infusion therapy at that time due to our lack of experience 
with the newly designed algorithm which was reserved for those who failed all 
conventional means of glycemic control. This inclusion criterion likely led to selection 
bias towards a more critically ill population than that identified by injury severity score 
alone. Additionally, the renal failure group contained eighteen patients with AKI and 
three with a history of CKD. It is unclear whether critically ill patients with AKI or CKD 
respond physiologically similar to each other to glycemic loads and insulin therapy 
during metabolic stress. Finally, the use of point-of-care blood glucose measurements is 
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not as accurate as serum glucose determinations from arterial blood samples and may 
result in about a 10% overestimation of actual glucose concentrations thereby missing 
potential hypoglycemic episodes.[56-58]  
Our work calls attention to the fragility of glycemic control for critically ill 
patients with renal failure. Clinicians should be cautioned regarding the routine use of 
continuous intravenous insulin infusion algorithms designed in patients with adequate 
renal function. The physiologic mechanism(s) responsible for hypoglycemia during 
concurrent continuous intravenous insulin therapy and specialized nutrition support for 
patients with renal failure and the development of a safe and efficacious intravenous 
insulin infusion algorithm deserves further study. 
 
Conclusions 
 Glycemic control for the critically ill, hyperglycemic trauma patient with renal 
failure is extremely challenging. Seventy-six percent of hyperglycemic patients with 
renal failure treated with a continuous intravenous insulin infusion had an occurrence of 
moderate hypoglycemia (BG < 60 mg/dL or 3.3 mmol/L) and 29% experienced an 
episode of severe hypoglycemia (BG < 40 mg/dL or 2.2 mmol/L) compared to 35% and 
0%, respectively, of hyperglycemic trauma patients without renal failure. This increase in 
hypoglycemic episodes occurred despite the use of a modified insulin infusion algorithm 
designed to provide a slower escalation in insulin infusion dosage rates than our 
conventional algorithm. The use of continuous intravenous insulin therapy should be used 
with extreme caution for hyperglycemic patients with renal failure due to the excessively 
high risk for hypoglycemia.  
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Table 1  Graduated continuous intravenous insulin infusion protocols 
Conventional algorithm[17] Modified algorithm for renal failure* 
BG , mg/dL  
    (mmol/L) 
 
Intervention BG (mg/dL) 









Stop RHI, give ½ amp D50W 
61 – 100§ 
(3.4 – 5.6) 
 
Decrease RHI by 50% 61 – 100 
(3.4 – 5.6) 
Decrease RHI by 50% 
101 – 125 
(5.7 – 6.9) 
 
No Change 101 – 125 
(5.7 – 6.9) 
 
No Change 
126 – 175 
(7.0 – 9.7)  
 
Increase RHI by 1 unit/hr 126 - 175 
(7.0 – 9.7)  
Increase RHI by 1 unit/hr 
176 – 200 
(9.8 – 11.1) 
 
Increase RHI by 2 units/hr 176 – 225 
(9.8 – 12.5) 
Increase RHI by 2 units/hr 
201 – 225 
(11.2 – 12.5) 
 
Increase RHI by 3 units/hr 226 – 275 
(12.6 – 15.3) 
Increase RHI by 3 units/hr 
226 – 250 
(12.6 – 13.9) 
 
Increase RHI by 4 units/hr 276 – 325 
(15.4 – 18.0) 
Increase RHI by 4 units/hr 
251 – 275 
(14.0 – 15.3) 
 
Increase RHI by 5 units/hr > 325 
(> 18.0) 
Increase RHI by 4 units/hr and 
call MD 
276 – 300 
(15.4 – 16.7) 
 
Increase RHI by 6 units/hr 
> 300 
(> 16.7) 
Increase RHI by 6 units/hr 
and call MD 
 
§Deviates from original publication[17]: BG < 70 mg/dL and BG 70 to 100 mg/dL. *This 
algorithm is not recommended for use in patients with acute kidney injury or chronic 
renal insufficiency. We subsequently have modified this algorithm following this study in 
an effort to develop a safe and effective RHI infusion algorithm for patients with acute 
kidney injury or chronic renal insufficiency requiring specialized nutrition support. 
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Additionally, we have plans to modify both our conventional and modified algorithms to 
provide 1 amp of D50W (50 g) for a BG < 40 mg/dl (2.2 mmol/L) with subsequent BG 
checks every 30 minutes until the BG is > 60 mg/dL. 
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Table 2 Patient demographics: Patients without renal failure (RF) versus those with RF 
Variable Without RF 
(n = 40) 
With RF 





33/7 19/2 NS 
Race 
     Caucasian (n) 
     African-American (n) 













     MVA (n) 
     Fall (n) 
     GSW (n) 














History of DM (n) 
 
16 (40%) 11 (52%) NS 
Age (yrs) 
 
57 + 16 60 + 16 NS 
Weight (kg) 
 
BMI (kg/m2)                  
 
99 + 33 
 
32 + 10                 
100 + 30 
 





                (g/L) 
1.9 + 0.5 
19 + 5 
2.1 + 0.8 




                    (mg/L) 
9.7 + 4.4 
97 + 44 
9.8 + 4.0 
98 + 40 
 
NS 
WBC count (cells/mm3) 
 
12.9 + 6.7 13.9 + 4.6 NS 
Serum creatinine (mg/dL) 
                             (μmol/L) 
 
1.2 + 0.5 
106 +  44 
3.2 + 1.8  
283 + 159 
0.001 
Predicted CrCl (mL/min) 
 
73 + 34  36 + 20 0.001 
PN/EN (n/n) 
  




39 + 53 
5/16 
 






14 (35%) 12 (57%) NS 
ISS 33 + 10 31 + 13 NS 
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ICU length of stay (d) 
 
36 + 37 27 + 14 NS 
Hospital length of stay (d) 
 
45 + 38 38 + 26 NS 
Survival (lived/died, n/n) 
 
22/18 17/4 NS 
 
BMI, body mass index; CrCl, creatinine clearance; DM, diabetes mellitus; EN, enteral 
nutrition; GSW, gun shot wound; ICU, intensive care unit; ISS, injury severity score; 




Table 3 Response to continuous intravenous infusion therapy: Trauma patients without 





(n = 40) 
With RF 
(n = 21) 
P 
Hospital day infusion initiated (d) 7.6 + 7.8 8.5 + 7.0 NS 
Day post initiation of PN/EN (d) 4.4 + 5.5 5.0 + 7.2 NS 
Duration of insulin infusion (d) 11.9 + 12.1 9.2 + 4.9 NS 
Average amount of insulin received 
(units/d) 
 
93 + 43 105 + 40 NS 
Average carbohydrate intake (g/d) 163 + 81 161 + 97 NS 
Hrs to achieve BG 70 - 149 mg/dL 
                               3.9 - 8.3 mmol/L 
 
5. 0 + 3.0 6.1 + 3.3 NS 
BG during insulin infusion (mg/dL) 122 + 15 133 + 14 0.01 
Hrs/d BG 70 - 149 mg/dL 
                 3.9 - 8.3 mmol/L 
 
19.6 + 4.7 16.1 + 3.3 0.001 
Hrs/d BG > 149 mg/dL 
                 > 8.3 mmol/L 
 
3.4 + 3.0 6.9 + 3.2 0.001 
Hrs/d BG < 70 mg/dL 
                 < 3.9 mmol/L 
 
0.7 + 0.8 1.4 + 1.1 0.01 
BG < 60 mg/dL (n, %) 
       < 3.3 mmol/L 
 
14 (35%) 16 (76%) 0.005 
BG  < 40 mg/dL (n, %) 
        < 2.2 mmol/L 
 
0 (0%) 6 (29%) 0.001 
 
BG, blood glucose concentration; EN, enteral nutrition; Hrs, hours; n, number of patients; 
NS, not significant; PN, parenteral nutrition 
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Table 4 Characteristics of patients with renal failure who developed severe 
hypoglycemia  
Variable With Severe 
Hypoglycemia 
(n = 6) 
Without Severe 
Hypoglycemia  





69 + 17 56 + 16 NS 
Weight (kg) 
 
90 + 22 104 + 32 NS 
Albumin (g/dL) 
                (g/L) 
1.9 + 0.7 
19 + 7 
2.1 + 0.9 




                    (mg/L) 
10.6 + 4.7 
106 + 47 
9.5 + 3.8 
95 + 38 
 
NS 
WBC count (cells/mm3) 
 
12.7 + 2.9 14.5 + 5.1 NS 
Serum creatinine (mg/dL) 
                             (μmol/L) 
 
2.8 + 0.9 
248 + 80 
3.3 + 2.1 
292 + 186 
NS 
Received hemodialysis (n,%) 
 
2 (33%)  6 (40%) NS 
History of DM (n, %) 
 
4 (67%) 7 (47%) NS 
Days of RHI infusion (d) 
 
8 + 4 10 + 5 NS 
Sepsis (n, %) 
 
4 (66%) 8 (53%) NS 
ISS 
 
26 + 9 28 + 14 NS 
Hospital length of stay (d) 
 
36 + 18 39 + 29 NS 
Survival (lived/died, n/n) 
 
6/0 11/5 NS 
Average BG (mg/dL) 
                      (mmol/L) 
 
137 + 16 
7.6 + 0.9 
131 + 13 
7.3 + 0.7 
NS 
Average RHI intake (units/d) 
 
100 + 52 107 + 36 NS 
Average CHO intake (g/d) 
 
157 + 106 163 + 97 NS 
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BG, blood glucose concentration; CHO, carbohydrate; DM, diabetes mellitus; ISS, injury 
severity score; RHI, regular human insulin; WBC, white blood cell
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Table 5  Reported incidence of severe hypoglycemia and renal failure from the major 
trials 
Trial      Prevalence of     
Renal Failure   Severe Hypoglycemia 
       (BG < 40 mg/dL or 2.2 mmol/L) 
Leuven 1[3]  Four patients with dialysis    5.1% 
   prior to ICU admission 
Leuven 2[31]  6.2% prior to ICU admission   18.7% 
20% with AKI 
NICE-Sugar[2] 35% with “renal dysfunction”   6.8% 
15.4% received CRRT 
VISEP[29]  31.1% with AKI    17.0% 
Glucontrol[30] 523 days of CRRT     8.7% 
 
AKI, acute kidney injury; BG, blood glucose; CRRT, continuous renal replacement 
therapy; ICU, intensive care unit
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Figure 1. Blood glucose response to continuous intravenous insulin infusion therapy for 
patients without renal failure (without RF) versus patients with renal failure (With RF). 
Blood glucose concentration (mmol/L) = 0.0551 X blood glucose concentration (mg/dL).  
NS, not significant. *denotes significant (p < 0.05) pair-wise differences between groups. 
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